Purpose To evaluate the correlation between change in FDG uptake before and after chemotherapy in hepatic metastases of colorectal carcinoma (HCRC) and a histopathologic tumor regression grade (TRG). Methods In patients with HCRC, PET/CT data prior to hepatic surgery were retrospectively analyzed under an IRB waiver. The maximum standard uptake value (SUV max ) was measured before and after chemotherapy. The relative change of FDG activity in the identified lesions was calculated (dSUV). Histopathological specimens of resected metastases were graded on a 5-score TRG scale. A TRG of 1-3 was rated as a responding to therapy, whereas TRG 4-5 were regarded as non-responding lesions.
Introduction
In the past decades the use of neoadjuvant chemotherapy before surgery for hepatic metastasis of colorectal carcinoma (HCRC) gained significance [1] . Thanks to the introduction of more effective chemotherapeutic agents and targeted agents for HCRC this approach improved the outcome [2] . The main intention thereby is to render primarily unresectable patients resectable [3, 4] . To determine the eligibility of patients preoperative 18 F-fluorodeoxyglucose (FDG) PET/CT has shown to reduce futile laparotomies since not only the liver but the entire body is evaluated and distant recurrences or progression can be detected [5] .
Metabolic alterations in tumor cells have been shown to occur before alterations in tumor size and might be a better indicative of tumor response to therapy [6] . Therefore, the preoperative FDG PET/CT scan has also been used for therapy response assessment [7] . For evaluation of tumor response with FDG PET, the European Organization for Research and Treatment of Cancer (EORTC) released a widely accepted standardization in 1999 [8] . However, since then different percentages of relative change in FDG uptake have been suggested, to distinguish complete or partial remission from stable or progressive disease.
EORTC guidelines suggested a partial remission with [15 % decrease in SUV after one cycle of chemotherapy, or [25 % decrease after more than one cycle [8] , others a decrease of [30 % for partial remission [9] .
These generalized guidelines for all solid tumor entities lack pathological correlates and cannot take variable biological tumor behaviour into account. Therefore, a correlation of the change in FDG measured as the relative change in SUV max with histopathological tumor regression grades (TRGs) for specific tumor types has been suggested [10] [11] [12] [13] . These studies showed that for locally advanced rectal cancer a decrease between 53 and 66 % in FDG activity correlated well with a good pathological response to chemo radiation therapy [10, 13] . On the other hand, the correlation between decrease in FDG uptake and histopathological response in esophageal carcinomas was not significant [11, 12, 14] .
Histopathological analysis of residual tumor viability with a TRG was initially proposed for rectal cancer, reaching from Grade 1 with complete fibrosis to Grade 5 with complete absence of regressive changes [15] . A modified version of this TRG scoring system has been suggested to assess the therapy response in HCRC [16] . With this score TRG responders had a significantly improved disease-free survival (DFS) and overall survival (OS) [16] .
To our knowledge no previous study investigated the correlation between TRG, and the relative change in FDG uptake before and after chemotherapy for HCRC. The aim of our analysis was to correlate the relative change in FDG uptake with TRG and to determine the optimal cut off to distinguish histopathological responders from nonresponders with FDG PET/CT.
Materials and methods

Patients
We consecutively screened all patients between June 2007 and July 2010 with colorectal carcinoma referred from the visceral surgery department to the division of nuclear medicine and selected those patients with HCRC who underwent FDG PET/CT before and after chemotherapy. Patients were eligible if the second FDG PET/CT was within 2-7 weeks after last chemotherapy. 69 patients met the inclusion criteria. 3 patients had partial liver resection between both scans and 2 patients had one FDG PET/CT examination in a different institution and were therefore excluded. Of the remaining 64 patients, 42 had surgery with resection of hepatic metastases within 8 weeks after FDG PET/CT [17, 18] . From the medical records, a clear correlation between pathology and FDG PET/CT was possible for 31 lesions (max 3 lesions per patient) in 23 patients (Fig. 1) .
PET/CT acquisition and analysis
All patients were examined using a routine clinical protocol on dedicated PET/CT scanners (GE Healthcare DSTX, 16-or 64-slices CT, 7-8 frames, frame time 1.5 or 2 min) with injection of 350 MBq FDG 45-60 min before examination. A low dose unenhanced CT-scan was performed for attenuation correction and used for anatomical localization (80 mA, 140 kV). Approximate total dose equivalent for the entire PET/CT examination =10 mSv. To reduce bladder activity patients had to urinate just before image acquisition [19] .
Image analysis was performed by a dual board certified nuclear medicine physician and radiologist (TFH), blinded for the results from histopathology. The activity in the identified lesions was measured as the maximum value in a volume of interest (VOI) around the whole selected lesion. The relative change in FDG activity between the two PET/ CT scans before and after neo-adjuvant (for resectable patients) or downstaging (for unresectable patients) chemotherapy was calculated (dSUV), Eq (1): dSUVð%Þ ¼ SUV max ðscan 2Þ À SUV max ðscan 1Þ SUV max ðscan 1Þ Â 100: Histopathological analysis
Histopathological specimens of resected metastases were evaluated for the proportion of viable tumor cells, tumor necrosis, and fibrosis in Hematoxylin and Eosin staining. TRG was graded on a 5-point scale based on the histological tumor response assessment described by RubbiaBrandt et al. [16] . TRG 1 signifies complete tumor regression showing only fibrosis as sign of regression and no residual cancer in the former metastasis. The amount of viable tumor cells increases with TRG whereas the extent of fibrosis decreases with complete absence in TRG 5.
Statistical analysis
The distribution of dSUV values for each histopathological TRG was analyzed using box plots. Correlation between TRG and dSUV was calculated with Pearson correlation. A receiver operator characteristic (ROC) curve was generated for dSUV and TRG responders versus non-responders. The area under the curve (AUC) was calculated and the optimal cut off point for the ROC curve determined using the Youden index (J value), calculated as the maximum of J = SN ? SP -1, where SN is sensitivity and SP is specificity, for each cut off volume [20] .
Results 31 resected liver lesions were identified in 23 patients. 19 of 23 patients were treated with folic acid and fluorouracil combined with either oxaliplatin or irinotecan. 4 patients were treated with fluorouracil and optional bevacizumab or oxaliplatin. Demographic details are listed in Table 1 .
In the baseline study the HCRC had SUV max values of 7.4 ± 3.7 (range 2.9-15.3). The SUV max for all lesions in the second scan was 3.5 ± 2.1 (range 1.6-12).
The histopathological analysis revealed complete fibrosis in 2 lesions (TRG 1), more fibrosis than residual viable tumor in 18 lesions (TRG 2 and 3) and more viable tumor than fibrosis in 11 lesions (TRG 4 and 5) ( Table 2) .
The relative change in SUV max for the five histological TRG grades is given in Fig. 2 with box plots. The correlation between TRG and dSUV was significant (correlation r = 0.48, p = 0.001, 2-tailed). The ROC curve revealed an AUC of 0.773 (95 % confidence interval 0.599-0.946), with an optimal cut off to distinguish responders from non-responders of dSUV -41 %, yielding a sensitivity, specificity, positive and negative predictive value and an accuracy of 72, 75, 83, 62 and 74 %, respectively (Fig. 3) .
With a cut off at dSUV -41 %, 15 lesions were regarded responding in FDG PET/CT CT and also histopathological responders (TRG 1-3). Figure 4 is an example of complete remission in PET/CT with no residual FDG uptake and a complete histological tumor regression (TRG 1). 13 lesions were non-responders in FDG PET/CT, histopathology however revealed response to therapy in 5 of these lesions (all lesions TRG 3). The mean dSUV overall was -41 ± 42 % (range -89.5 to 126 %). All lesions with SUV PET I (mean ± SD) 14.1 ± 1.7 9.1 ± 4.2 7.3 ± 3.6 5.9 ± 2.5 5.1 ± 0.3 SUV PET II (mean ± SD) 2.1 ± 0.7 2.8 ± 0.9 3.0 ± 0.8 3.7 ± 2.0 9.1 ± 4.1 dSUV (mean ± SD %) -84.7 ± 6.9 -66.8 ± 12.5 -48.6 ± 24.5 -32.4 ± 29.1 76 ± 70
With cut off (-41 %) PET responding/non-resp. 2/0 4/0 9/5 3/6 0/2 an increase in dSUV showed no signs of histopathological response (TRG 4 or 5) ( Table 3 ). Figure 5 illustrates a case of increased FDG uptake in the second PET/CT, corresponding to a high degree of remaining vital tumor cells analogous to TRG 5. In one lesion PET/CT suggested therapy response (dSUV) -76 %; histopathology revealed a mixed image with areas of extended necrosis (Fig. 6C 1 ) , and areas of more vital cells than fibrosis (TRG 4, Fig. 6C 2 ) . For six patients two lesions were included in the study, of those two patients had a decrease in dSUV of less than 41 % in both lesions and were regarded as non-responders, whereas four patients decreased more than 41 % in both lesions. In one patient 3 lesions could be identified on PET/ CT and pathology reports and were included in the study: two lesions decreased less than 41 % and one lesion decreased 51 % between the two PET/CT scans, resulting in a mixed response.
Discussion
The objective of this study was to assess the diagnostic accuracy of response assessment with FDG PET/CT in patients with HCRC treated with neoadjuvant chemotherapy by correlating change in FDG uptake with histopathological tumor response.
Overall, change in FDG activity in HCRC after chemotherapy correlated significant with overall survival in several studies and FDG PET seems to be a reliable prognostic tool to predict the efficacy of preoperative chemotherapy [18, 21] .
Previous recommendations for therapy assessment with FDG PET/CT suggested a decrease of 15-30 % for a partial metabolic response [8, 9] . In the present study a significant correlation between FDG uptake and the TRG system for HCRC was found (p = 0.001). A cut off at -41 % dSUV for responding lesions could be identified resulting in a positive predictive value of over 83 %. Therefore, similar to the results for locally advanced rectal cancer the requested decrease in SUV max after neoadjuvant chemotherapy might be higher for HCRC than the currently generally recommended 15-30 % to reflect histopathological tumor regression [10, 13] . This underlines the need to determine PET-response criteria individually for each cancer entity as it has been demonstrated for esophageal cancer as well [11, 12] . Furthermore, an increase in dSUV was predictive for histopathological non-response in all cases.
FDG PET/CT cannot replace a histopathological work up after tumor resection. However, preoperative FDG PET has shown to detect distant recurrences and is therefore an efficient tool in the selection of resectable patients after neo-adjuvant chemotherapy [5] . Additionally, reliable noninvasive assessment of treatment efficacy can be helpful for the oncologist for further treatment planning of the patients, since the same chemotherapy regimen can be continued, e.g., in difficult surgical situations when complete resection in a single step procedure is not possible or for completion of neo-adjuvant treatment. A limitation of the presented data is the retrospective nature, which makes an accurate identification and correlation of lesions in pathology reports with the FDG PET/ CT images difficult. We were therefore limited to 31 lesions. This also limited the possibility for outcome analysis; since only 23 patients were included we focused on the lesion-based analysis only.
Larger studies analyzing the correlation between change in SUV and histopathological tumor response are desirable, ideally in a prospective setting with response assessment scheduled within a standardized timeframe after completion of neoadjuvant therapy and imaging protocols [22] . In the present study, the variable time between chemotherapy and surgery among different patients limits the informative value of the histopathological response scoring. However, this was still in accordance with the retrospective manner and selection of patients with different therapies and time regimes that were used to predict pathological response [16] . Also the chosen time frame of 8 weeks between PET and surgery is within the range of previously published studies for FDG PET/CT response assessment for HCRC [18] . A further limitation is that we did not have contrast enhanced CT-scans. Therefore, morphologic response assessment was not performed and a comparison of metabolic versus morphologic response not possible.
To strengthen or modify the result of 41 % decrease in FDG uptake presented in this study, larger cohorts imaged with strictly defined protocols will be required. However, these are the first results analyzing the correlation between FDG decrease and TRG for HCRC and they suggest that we might need to reevaluate the partial metabolic response criterion in FDG PET/CT therapy response assessment and seek individual thresholds for different tumors.
Conclusion
A relative change in FDG activity of more than 41 % can be a prognostic tool to predict histopathological response to chemotherapy in HCRC. A relative increase or a low-to- moderate decrease in SUV indicated that hepatic lesions did not respond to therapy.
